Medicine Man

McKinnell, Hank; Gibbs, Lisa
June 2001
Money;Jun2001, Vol. 30 Issue 6, p37
Presents an interview with Henry McKinnell, chief executive officer of pharmaceutical company Pfizer. Competition between Pfizer's drug Lipitor and Astra-Zeneca's Crestor; Product launches planned for 2001; Reasons for a slower revenue growth in 2000.


Related Articles

  • Stockholders protest Pfizer's drug prices. Lenzer, Jeanne // CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p24 

    Reports on the criticism of the Interfaith Center on Corporate Responsibility (ICCR) against the pricing practices of a number of drug companies. Proposal on drug access submitted by ICCR at Pfizer's annual meeting in 2004; Statement from Adrian Dominican Sisters' coordinator Margaret Weber...

  • Pfizer CEO leaves early… and takes $200m with him.  // European Pharmaceutical Executive;Feb/Mar2007, p8 

    The article reports on the controversial financial package given to Pfizer's ousted chief executive officer Henry McKinnell. In a filing with the U.S. Securities and Exchange Commission, McKinnell will receive over $180 million consisting of stock totaling more than $20.7 million, $77.9 million...

  • A singular path to global power. Koberstein, Wayne // Pharmaceutical Executive;Jul97, Vol. 17 Issue 7, p40 

    Focuses on Pfizer's global expansion strategies under Henry A. McKinnell Jr., president of the drug company's worldwide group. Integration of American and foreign pharmaceutical divisions into a single organization; Creation of the Pfizer Health Solutions unit; Comarketing alliance with...

  • Muscular marketing.  // Pharmaceutical Executive;Jul97, Vol. 17 Issue 7, p42 

    Presents an interview with Henry A. McKinnell Jr., president of Pfizer's worldwide group. Secret of Pfizer's marketing and sales success; Increased use of interactive media for marketing purposes; Relationships with agencies and media vendors; Role of Pfizer's Consumer Health Care business in...

  • COMPANY SPOTLIGHT: Pfizer.  // PharmaWatch: CNS;February 2003, Vol. 2 Issue 2, p18 

    Presents a corporate profile of pharmaceutical company Pfizer. Company overview; Business description; Key employees including president and chairman Henry A. McKinnell and vice-president John F. Niblack; Strengths and weaknesses; Financial status; Products and services.

  • No magic potion among Pfizer's drugs. Harrington, John // Crain's New York Business;04/23/2001, Vol. 17 Issue 17, p46 

    Reports on an increase in the earnings of New York City-based pharmaceutical firm Pfizer Inc. for the first quarter of the year 2001. Factors behind the increase; Percentage of revenue growth achieved by the firm; Business strategies to further increase the firm's earnings.

  • A Dose of Strong Medicine. P., Shankar // njbiz;6/23/2003, Vol. 16 Issue 25, p35 

    Focuses on the financial performance of the pharmaceutical company Pfizer in New York City. Income posted by the company in 2002; Plans of the company for its business; Drugs that face the loss of their patents.

  • Pfizer Offers Solid 3Q Results.  // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p3 

    Reports on the performance of pharmaceutical company Pfizer as of October 22, 2001. Factors contributing to Pfizer's strong performance; Net income of the company in the third quarter of 2001; Percentage of the market held by the Pfizer drug Lipitor.

  • Pfizer Maintains Steady 3Q Growth.  // Chemical Market Reporter;10/21/2002, Vol. 262 Issue 14, p3 

    Reports on the growth in profits of the pharmaceutical company Pfizer Inc. in the third quarter of 2002. Percentage rise in the company's earnings; Percentage rise in sales of the company; Drugs that contributed to higher sales.


Read the Article

Other Topics